Net margin is calculated as Net Income divided by its Revenue. Prothena's Net Income for the
three
months ended in Mar. 2026 was €28.30 Mil. Prothena's Revenue for the
three
months ended in Mar. 2026 was €44.19 Mil. Therefore, Prothena's net margin for the quarter that ended in Mar. 2026 was 64.05%.
The historical rank and industry rank for Prothena's Net Margin % or its related term are showing as below:
STU:0PT'
s Net Margin % Range Over the Past 10 Years
Min: -16297.91 Med: -1538.71 Max: 33.39
Current: -260.92
STU:0PT's Net Margin % is ranked worse than 63.21% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs STU:0PT: -260.92
Prothena (STU:0PT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Prothena Net Margin % Related Terms
Prothena Net Margin % Historical Data
* Premium members only.
The historical data trend for Prothena's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0PT vs EDIT, ACHV, XOMA: Net Margin % Comparison
For the Biotechnology subindustry, Prothena's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prothena Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prothena's Net Margin % distribution charts can be found below:
* The bar in red indicates where Prothena's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prothena (STU:0PT) has a Net Margin % of 64.05% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Prothena and its competitors. According to the industry distribution chart, Prothena ranks #598 out of 946 companies in the Biotechnology industry, placing it in the top 63.2%.
Is Prothena's Net Margin % too high?
Prothena's current Net Margin % is 64.05%. Based on the distribution chart, Prothena ranks #598 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Prothena has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Prothena's Net Margin % compare to EDIT and ACHV?
According to the Biotechnology industry distribution chart, Prothena ranks #598 out of 946 companies for Net Margin %. This places Prothena in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Prothena and its competitors. Prothena's current Net Margin % is 64.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prothena stock overvalued right now?
Prothena (STU:0PT) has a current Net Margin % of 64.05%. The stock's GF Value™ is €12.85, compared to a current price of €8.72 — trading 32.2% below its estimated fair value. The current Net Margin % is 64.05%. Prothena's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Prothena (STU:0PT), the current Net Margin % is 64.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prothena (STU:0PT) Overvalued in 2026?
Based on GuruFocus' analysis, Prothena stock appears to be undervalued.
The current stock price of €8.72 is trading 32.2% below its estimated GF Value™ of €12.85.
Key valuation signals for STU:0PT:
Net Margin %: 64.05%
GF Value™: €12.85 vs. price of €8.72 (32.2% below fair value)
No single metric tells the full story. See the STU:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
78GF Score
Get the complete analysis for STU:0PT
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0PT has been successfully added to your 
